NF1 mutation
|
CNS Tumor
|
NF1 mutation
|
CNS Tumor
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
NF1 mutation
|
Glioma
|
NF1 mutation
|
Glioma
|
trametinib Sensitive: C3 – Early Trials
|
trametinib Sensitive: C3 – Early Trials
|
NF1 mutation
|
Melanoma
|
NF1 mutation
|
Melanoma
|
vemurafenib Resistant: C3 – Early Trials
|
vemurafenib Resistant: C3 – Early Trials
|
NF1 mutation
|
Thyroid Gland Anaplastic Carcinoma
|
NF1 mutation
|
Thyroid Gland Anaplastic Carcinoma
|
atezolizumab + cobimetinib Sensitive: C3 – Early Trials
|
atezolizumab + cobimetinib Sensitive: C3 – Early Trials
|
NF1 mutation
|
CRC
|
NF1 mutation
|
CRC
|
AZD6738 Sensitive: C3 – Early Trials
|
AZD6738 Sensitive: C3 – Early Trials
|
NF1 mutation
|
Multiple Myeloma
|
NF1 mutation
|
Multiple Myeloma
|
MEK inhibitor Sensitive: C3 – Early Trials
|
MEK inhibitor Sensitive: C3 – Early Trials
|
NF1 mutation
|
Solid Tumor
|
NF1 mutation
|
Solid Tumor
|
selumetinib Resistant: C3 – Early Trials
|
selumetinib Resistant: C3 – Early Trials
|
NF1 mutation
|
Melanoma
|
NF1 mutation
|
Melanoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
NF1 mutation
|
Melanoma
|
NF1 mutation
|
Melanoma
|
PD1 inhibitor + MEK inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor + MEK inhibitor Sensitive: C3 – Early Trials
|
NF1 mutation
|
Thyroid Gland Medullary Carcinoma
|
NF1 mutation
|
Thyroid Gland Medullary Carcinoma
|
vandetanib Sensitive: C4 – Case Studies
|
vandetanib Sensitive: C4 – Case Studies
|
NF1 mutation
|
Sarcoma
|
NF1 mutation
|
Sarcoma
|
SAR442720 Sensitive: C4 – Case Studies
|
SAR442720 Sensitive: C4 – Case Studies
|
NF1 mutation
|
Melanoma
|
NF1 mutation
|
Melanoma
|
VTX-11e Resistant: D – Preclinical
|
VTX-11e Resistant: D – Preclinical
|
NF1 mutation
|
Melanoma
|
NF1 mutation
|
Melanoma
|
PD-0325901 Sensitive: D – Preclinical
|
PD-0325901 Sensitive: D – Preclinical
|
NF1 mutation
|
Neurofibrosarcoma
|
NF1 mutation
|
Neurofibrosarcoma
|
DR6MP + JHU395 Sensitive: D – Preclinical
|
DR6MP + JHU395 Sensitive: D – Preclinical
|
NF1 mutation
|
Neurofibrosarcoma
|
NF1 mutation
|
Neurofibrosarcoma
|
DR6MP Sensitive: D – Preclinical
|
DR6MP Sensitive: D – Preclinical
|
NF1 mutation
|
Neurofibrosarcoma
|
NF1 mutation
|
Neurofibrosarcoma
|
MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical
|
MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical
|
NF1 mutation
|
NSCLC
|
NF1 mutation
|
NSCLC
|
ERAS-601 Sensitive: D – Preclinical
|
ERAS-601 Sensitive: D – Preclinical
|